Showing 8341-8350 of 8647 results for "".
- Eyepatch With Dissolvable Needles Used to Treat Eye Diseasehttps://modernod.com/news/eyepatch-with-dissolvable-needles-used-to-treat-eye-disease/2479667/A team of researchers affiliated with several institutions in Singapore has developed an eyepatch with dissolvable needles for use in treating eye diseases, according to a report in Medical Xpress.
- New Melanoma Treatments Do Not Supplant Surgery as First-Line Therapyhttps://modernod.com/news/new-melanoma-treatments-do-not-supplant-surgery-as-first-line-therapy/2479670/Although several new melanoma treatments have shown promise, none replaces surgery as the primary therapy yet, according to updated guidelines from the American Academy of Dermatology (AAD), as reported in Reuters Health. “Su
- Takeda, Shire Shareholders to Vote on Merger Deal Next Monthhttps://modernod.com/news/takeda-shire-shareholders-to-vote-on-merger-deal-next-month/2479678/Takeda and Shire announced that shareholders will vote on December 5 on the companies’ proposed $62-billion merger, with the Japanese drugmaker targeting January 8, 2019 for closing of the deal. Takeda CEO Christophe Weber remarked “with the date of our extraordinary general meeting (
- RetiPharma Secures Funding to Develop Treatments of Degenerative Eye Disordershttps://modernod.com/news/retipharma-secures-funding-to-develop-treatments-of-degenerative-eye-disorders/2479680/RetiPharma has announced that it has secured funding from the Novo Nordisk Foundation’s BioInnovation Institute (BII). The funding will be used to prepare its lead drug RP001 for a clinical proof-of-concept study in patients with retinal detachment as well as to in source additional compounds usi
- Prospective Study for NaturalVue Multifocal Demonstrates Decreased Refractive Error Change in Fast-Progressing Myopic Childrenhttps://modernod.com/news/prospective-study-for-naturalvue-multifocal-demonstrates-decreased-refractive-error-change-in-fast-progressing-myopic-children/2479681/Thomas Aller, OD, presented updated findings from a prospective clinical trial of NaturalVue (etafilcon A) 1 Day Multifocal Contact Lenses at a briefing for media and industry leaders at the American Academy of Optometry (AAO) Conference in San Antonio on November 9. The NaturalVue portfolio of p
- Research Exposes Disparity Between ECPs’ Personal Wearing Habits and Prescribing Habits for Healthiest Contact Lens Materialhttps://modernod.com/news/research-exposes-disparity-between-ecps-personal-wearing-habits-and-prescribing-habits-for-healthiest-contact-lens-material/2479687/New data from CooperVision shows a disparity between what eye care professionals (ECPs) in the United States choose for their personal contact lens wear versus what they prescribe for patients. Among 183 surveyed U.S. optometrists who wear 1-day contact lenses, 72% prefer a silicone hydrogel prod
- EHR Medication Lists Inaccurate, Incomplete, Blood Tests Showhttps://modernod.com/news/ehr-medication-lists-inaccurate-incomplete-blood-tests-show/2479689/Researchers who checked patients’ blood samples for medication concentration found that more than half were taking prescription and/or over-the-counter drugs not listed in their electronic health record (EHR), indicating potential threats to patient safety, according to a Medscape
- Bausch’s Papa Says ‘Transformation on Track’ as Debt Paydown Continueshttps://modernod.com/news/bauschs-papa-says-transformation-on-track-as-debt-paydown-continues/2479690/The turnaround at Quebec-based Bausch Health Cos. appeared to take another step forward Tuesday, after the company reported positive organic growth for the third quarter, sending shares up more than five percent in Toronto, according to a Financial Post
- Pressure Intensifies to Lower Drug Priceshttps://modernod.com/news/pressure-intensifies-to-lower-drug-prices/2479696/The price of ophthalmic drugs varies widely in the United States, and this can adversely affect patient care, data from a new study show, according to a report in Medscape. “Our patients are the ones who are suffering because
- New Data from Johnson & Johnson Vision Highlights the Need and Potential Standards for Evidence-Based Decision-Making in Myopiahttps://modernod.com/news/new-data-from-johnson-johnson-vision-highlights-the-need-and-potential-standards-for-evidence-based-decision-making-in-myopia/2479698/Johnson & Johnson Vision announced that Noel A Brennan, PhD, the company’s Global Platform Lead for Myopia Control, will present data on myopia progression and investigational methods to control it at the 2018 American Academy of Optometry Annual Meeting, held November 7-10 in San Antonio, Te